These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 36016185)

  • 21. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study.
    Sebastian J; Gurumurthy P; Ravi MD; Ramesh M
    Ther Adv Vaccines Immunother; 2019; 7():2515135519889000. PubMed ID: 31799496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Refractory Longitudinally Extensive Transverse Myelitis after Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in a Japanese Man.
    Miyaue N; Yoshida A; Yamanishi Y; Tada S; Ando R; Hosokawa Y; Yabe H; Nagai M
    Intern Med; 2022 Mar; 61(5):739-742. PubMed ID: 34897155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality.
    Martins-Filho PR; Santana RRR; Cavalcante TF; Barboza WS; de Souza MF; Góes MAO; Fontes ÂMB; da Silva MEL; Tanajura DM
    Rev Panam Salud Publica; 2022; 46():e110. PubMed ID: 36016838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
    Jeon M; Kim J; Oh CE; Lee JY
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
    Logunov DY; Dolzhikova IV; Zubkova OV; Tukhvatullin AI; Shcheblyakov DV; Dzharullaeva AS; Grousova DM; Erokhova AS; Kovyrshina AV; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Lubenets NL; Egorova DA; Shmarov MM; Nikitenko NA; Morozova LF; Smolyarchuk EA; Kryukov EV; Babira VF; Borisevich SV; Naroditsky BS; Gintsburg AL
    Lancet; 2020 Sep; 396(10255):887-897. PubMed ID: 32896291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine safety surveillance in Canada: Reports to CAEFISS, 2017.
    Johnson K; Anyoti H; Coulby C
    Can Commun Dis Rep; 2018 Dec; 44(12):324-330. PubMed ID: 31517950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines.
    Andrews N; Tessier E; Stowe J; Gower C; Kirsebom F; Simmons R; Gallagher E; Thelwall S; Groves N; Dabrera G; Myers R; Campbell CNJ; Amirthalingam G; Edmunds M; Zambon M; Brown K; Hopkins S; Chand M; Ladhani SN; Ramsay M; Lopez Bernal J
    N Engl J Med; 2022 Jan; 386(4):340-350. PubMed ID: 35021002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
    Masuka JT; Khoza S
    BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016).
    Mauro AB; Fernandes EG; Miyaji KT; Arantes BA; Valente MG; Sato HK; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2019 Sep; 61():e43. PubMed ID: 31531621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.
    Hu R; Peng S; Liu Y; Tang F; Wang Z; Zhang L; Gao J; Guo H
    BMC Public Health; 2021 Jul; 21(1):1338. PubMed ID: 34229643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
    Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
    BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.